Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients

Advances in Therapy

Volumn 31, Issue 2, 2014, Pages 217-233

  Agabiti Rosei, Enrico ^a   Manolis, Athanasios ^b   Zava, Dario ^c   Omboni, Stefano ^d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF ATHENS   (Greece)

^c Istituto Lusofarmaco d'Italia   (Italy)

^d ITALIAN INSTITUTE OF TELEMEDICINE   (Italy)

Author keywords

Ambulatory blood pressure monitoring; Cardiology; Essential hypertension; Hydrochlorothiazide; Irbesartan; Office blood pressure; Zofenopril

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS ZOFENOPRIL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CAPTOPRIL; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899107827     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0090-8     Document Type: Article

References (53)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23. (Pubitemid 40138015)
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. (Pubitemid 35472129)
3. Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-64.
4. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35. (Pubitemid 37410190)
5. The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-53.
6. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41.
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.
8. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-31. (Pubitemid 38781102)
9. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-357.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW,Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72. (Pubitemid 37430158)
11. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther. 2003;1:43-50.
12. Ambrosioni E. Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs. 2007;7:17-24. (Pubitemid 46698512)
13. Borghi C, Bacchelli S, Degli Esposti D. Long-term clinical experience with zofenopril. Expert Rev Cardiovasc Ther. 2012;10:973-82.
14. Borghi C, Ambrosioni E, Omboni S, et al. Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. J Hypertens. 2013;31:1256-64.
15. Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of myocardial infarction long-term evaluation. Am J Hypertens. 1999;12:665-72. (Pubitemid 29322838)
16. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press. 2007;2(Suppl):25-30.
17. Lacourciere Y, Provencher P. Comparative effects of zofenopril and HCTZ on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol. 1989;27:371-6. (Pubitemid 19097449)
18. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press. 2007;2(Suppl): 19-24.
19. Mallion JM. An evaluation of the initial and longterm antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press. 2007;2(Suppl):13-8.
20. Malacco E, Piazza S, Omboni S, Zofenopril Study Group. Zofenopril versus lisinopril in the treatment of essential hypertension in elderly patients: a randomised, double-blind, multicentre study. Clin Drug Investig. 2005;25:175-82. (Pubitemid 40460643)
21. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press. 2007;2(Suppl):7-12.
22. Leonetti G, Rappelli A, Omboni S, on behalf of the study group. A similar 24-h blood pressure control is obtained by zofenopril and candesartan in primary hypertensive patients. Blood Press. 2006;15(Suppl 1):18-26. (Pubitemid 43347949)
23. Borghi C, Cicero AF. The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review. High Blood Press Cardiovasc Prev. 2012;19:19-31.
24. Bramlage P, Durand-Zaleski I, Desai N, Pirk O, Hacker C. The value of irbesartan in the management of hypertension. Expert Opin Pharmacother. 2009;10:1817-31.
25. Omboni S, Malacco E, Parati G. Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions. Cardiovasc Ther. 2009;27:275-88.
26. Zanchetti A, Parati G, Malacco E. Zofenopril plus hydrochlorothiazide: combination therapy for the treatment of mild to moderate hypertension. Drugs. 2006;66:1107-15. (Pubitemid 43945870)
27. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-87. (Pubitemid 46924065)
28. Rogoza AN, Pavlova TS, Sergeeva MV. Validation of A&D UA-767 device for the self-measurement of blood pressure. Blood Press Monit. 2000;5:227-31.
29. Palatini P, Frigo G, Bertolo O, Roman E, Da Cortà R, Winnicki M. Validation of the A&D TM-2430 device for ambulatory blood pressure monitoring and evaluation of performance according to subjects' characteristics. Blood Press Monit. 1998;3:255-60. (Pubitemid 28521776)
30. MOREPRESS website. Monitoring remotely blood pressure. http://www.morepress.net. Accessed December 20, 2013.
31. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16:1685-91. (Pubitemid 28515496)
32. Parati G, Omboni S, Palatini P, et al. Italian society of hypertension guidelines for conventional and automated blood pressure measurement in the office, at home and over 24 hours. High Blood Press Cardiovasc Prev. 2008;15:283-310.
33. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443-62. (Pubitemid 34208333)
34. Working Party of the International Diabetes Federation (European Region). Hypertension in people with type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabet Med. 2003;20:972-87.
35. Elliot WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens. 2001;14(9 Pt 2):291S-5S.
36. Parati G, Omboni S, Malacco E. Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure. Blood Press. 2006;15(Suppl 1):7-17. (Pubitemid 43347948)
37. Neutel JM, Smith D. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/ hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. J Int Med Res. 2005;33:620-31. (Pubitemid 43012617)
38. Schrader J, Bramlage P, Lüders S, Thoenes M, Schirmer A, Paar DW. BP goal achievement in patients with uncontrolled hypertension: results of the treat-to-target post-marketing survey with irbesartan. Clin Drug Investig. 2007;27:783-96. (Pubitemid 47529294)
39. Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the treat to target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol. 2007;6:12.
40. Sun NL, Jing S, Chen J. The control rate of irbesartan/ hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2005;33:618-21. (Pubitemid 41371808)
41. Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R, COmparative Study of Efficacy of Irbesartan/HCTZ with Valsartan/HCTZ Using Home Blood Pressure Monitoring in the TreAtment of Mild-to-Moderate Hypertension (COSIMA) Investigators. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens. 2005;18:1482-8.
42. Neutel JM, Saunders E, Bakris GL, et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005;7:578-86.
43. Coca A, Calvo C, Garc?́a-Puig J, et al. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL). Clin Ther. 2002;24:126-38. (Pubitemid 34117529)
44. Lacourcière Y. A multicenter, randomized, doubleblind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin Ther. 2000;22:1213-24.
45. Chiou KR, Chen CH, Ding PY, et al. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension. Zhonghua Yi Xue Za Zhi (Taipei). 2000;63:368-76. (Pubitemid 30390048)
46. Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens. 1998;12:203-8. (Pubitemid 28140291)
47. Angulo E, Robles NR, Grois J, Barquero A, Pérez Miranda M. Comparison of the antihypertensive activity of fosinopril and irbesartan (in Spanish). An Med Interna. 2002;19:571-5. (Pubitemid 35429241)
48. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004;44:6-11. (Pubitemid 38823477)
49. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J. 2004; 148:e5.
50. Bramlage P. Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension. Vasc Health Risk Manag. 2009;5:213-24.
51. Forni V, Wuerzner G, Pruijm M, Burnier M. Long-term use and tolerability of irbesartan for control of hypertension. Integr Blood Press Control. 2011;4:17-26.
52. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462-6. (Pubitemid 27077826)
53. Rebuzzi AG, Quaranta G, Liuzzo G, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol. 1998;82:715-9.